Skip to main content

Table 6 Clinicopathological characteristics associated with disease-free survival and overall survival in patients with breast cancer

From: E-cadherin genetic variants predict survival outcome in breast cancer patients

Characteristics

Disease-free survival

Overall survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Agea

0.74

0.51–1.08

0.121

ni

  

0.75

0.33–1.68

0.487

ni

  

Menopausal statusb

0.92

0.66–1.28

0.638

ni

  

0.87

0.42–1.76

0.702

ni

  

Tumor sizec

1.87

1.33–2.64

0.0003

1.80

1.27–2.56

0.001

1.44

0.69–3.02

0.326

ni

  

Lymph node involvementd

1.75

1.22–2.51

0.002

1.66

1.14–2.40

0.007

2.97

1.21–7.30

0.017

3.26

1.22–8.69

0.018

Metastasisd

3.03

1.47–6.22

0.003

ni

  

5.64

1.67–19.01

0.005

ni

  

SBR gradee

1.09

0.77–1.56

0.599

ni

  

2.29

1.08–4.84

0.030

2.20

1.00–4.81

0.048

Histologyf

1.62

0.82–3.20

0.157

ni

  

0.80

0.11–5.92

0.833

ni

  

Estrogen receptord

1.34

0.91–1.95

0.127

ni

  

0.73

0.33–1.60

0.435

ni

  

Progesteron receptord

1.16

0.80–1.67

0.419

ni

  

0.88

0.40–1.95

0.763

ni

  

Her-2 statusd

1.03

0.44–2.40

0.938

ni

  

0.67

0.06–7.44

0.746

ni

  

CDH1 −347 G/GA g

0.92

0.63–1.35

0.694

ni

  

0.09

0.01–0.68

0.020

0.12

0.01–0.89

0.039

CDH1 −160 C/A g

0.92

0.66–1.28

0.650

ni

  

1.27

0.62–2.63

0.505

ni

  

CDH1 +54 C/T g

0.98

0.69–1.40

0.951

ni

  

0.52

0.26–1.06

0.075

0.40

0.18–0.87

0.022

  1. HR hazard ratio; ni not included in multivariate analysis
  2. a≤40 versus >40 years
  3. bNon menopausal versus menopausal
  4. cT1–T2 versus T3–T4
  5. dNegative versus positive
  6. eSBR 1–2 versus SBR 3
  7. fDuctal invasive carcinoma versus Lobular invasive carcinoma
  8. gHomozygous wild allele type versus heterozygous and mutates homozygous allele types